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Abstract 
Prostate cancer is the second leading cause of cancer-related death in American men. Alt-
hough most prostate cancers are initially androgen-dependent and respond to androgen 
ablation therapy, majority of them eventually relapse and progress into incurable castra-
tion-resistant (or hormone refractory) prostate cancer. The underlying mechanisms are the 
focus of intensive investigation for development of more effective treatment. Mounting evi-
dence from both clinical and basic research has demonstrated that the activity of the androgen 
receptor (AR) is still required for castration-resistant prostate cancer.  Multiple mechanisms 
by which AR is re-activated under androgen-depleted conditions may be involved in the 
development of castration resistance. The recent identification of AR splicing variants may add 
another layer of complexity in AR biology. The present review summarizes recent progress in 
study of AR splicing variants in prostate cancer. 
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Prostate cancer and AR 
Prostate  cancer  is  the  second  leading  cause  of 
cancer-related death in American men [1]. Majority of 
prostate cancers are initially androgen-dependent and 
respond  to  androgen  ablation  therapy  well,  with  a 
significant temporary remission. However, over 95% 
of hormone-responsive tumors eventually relapse and 
progress  into  incurable  castration-resistant  (or  hor-
mone  refractory)  prostate  cancer.  The  underlying 
mechanisms are the focus of intensive investigation 
for development of more effective treatment.  
The androgen receptor (AR) is a key transcrip-
tion factor that is activated by androgens and trans-
duces  androgen  signaling  in  prostate  cells  [2,  3]. 
Mounting evidence from both clinical and basic re-
search has demonstrated that AR activity is still re-
quired  for  castration-resistant  prostate  cancer  [4-7]. 
The mechanisms by which AR is re-activated under 
androgen-depleted  conditions  have  yet  to  be  fully 
elucidated. Mutation and amplification of  AR gene, 
alteration in protein kinases, growth factors, nuclear 
receptor  coactivators,  steroid  metabolism  enzymes 
and alternative splicing variants have been proposed 
to  modulate  AR  signaling  and  may,  therefore,  con-
tribute to castration resistance [8-15]. In this review, 
we will focus on the recent progress in study of AR 
splicing variants in prostate cancer. 
History of AR short form variants  
The full-length cDNA of the AR gene was first 
reported in 1988 [16, 17]. The major transcript derived 
from the AR gene in prostate cells, designated as AR 
transcript  variant  1  (GI:  21322251)  in  Genbank,  en-
codes a 110-kDa protein with four major functional 
domains  including  an  N-terminal  transactivation 
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domain (NTD), a DNA-binding domain (DBD), Hinge 
domain (H) and a C-terminal ligand-binding domain 
(LBD) (Figure 1). Although the LBD is responsible for 
binding to androgen and some co-factors, it may also 
serve as a negative regulator of AR transcription ac-
tivity based on several observations that deletion of 
LBD  generates  androgen-independent  constitutively 
active AR mutants [18-20]. However, it was unclear at 
that time whether such constitutively active AR iso-
form(s)  were  naturally  expressed  in  human  tissues 
and if they did exist, what were the functions of these 
AR short form variants?  
 For  more  than  a  decade,  researchers  have  ob-
served that, in addition to the well-studied 110-kDa 
AR  protein,  some  lower  molecular-weight  protein 
bands  are  detectable  by  an  antibody  for  the 
N-terminal region of AR in some AR-expressing cell 
lines.  However,  the  explanation  for  the  origins  of 
these AR short form variants was quite controversial. 
At least four potential mechanisms underlying gen-
eration of short form AR proteins were proposed: (1) 
alternative  translation  start  codons;  (2)  proteolytic 
cleavage;  (3)  premature  stop  codon  resulted  from 
mutation; and (4) alternative transcription start site. 
 In  1994,  Wilson  and  McPhaul  described  two 
forms, 110-kDa and 87-kDa, of AR protein are present 
in human genital skin fibroblasts [21]. They further 
showed that the 87-kDa isoform (AR-A) contains an 
intact  C  terminus  but  lacks  the  normal  N  terminus 
found in the 110-kDa isoform (AR-B). They proposed 
that the AR-A is due to translation initiation of AR 
protein  at  the  internal  Methionine  188  residue  of 
AR-B. They also suggested that AR-A and AR-B may 
differ in their ability to activate target genes and reg-
ulated  differently  in  various  cell  types,  which  are 
reminiscent of the A and B forms of human proges-
terone receptor [21]. In 2001, Gregory et al. reported 
that the AR short forms similar to that of the previ-
ously  described  87-kDa  AR-A  are  derived  from  in 
vitro proteolytic cleavage of N- or C-terminal regions 
of AR during cell extraction and storage [22]. In 2003, 
Tepper et al. reported an in-frame tandem duplication 
of exon 3 of AR in CWR22Rv1 cells. This insertional 
mutation was accompanied by a truncated AR protein 
of 75-80 kDa. Furthermore, they showed that the short 
form AR in CWR22Rv1 cells was a C-terminal trun-
cated AR (referred as ARΔLBD) which lacks the LBD. 
The  ARΔLBD  exhibits  constitutive  nuclear  localiza-
tion  and  DNA  binding  [23].  In  addition,  Libertini 
reported that the calcium-sensitive calpain could re-
move the AR C-terminal LBD and generate a consti-
tutively active AR protein in in vitro and in vivo anal-
ysis [24]. They further showed that this truncated AR 
is expressed at a higher level in several tumors com-
pared with benign prostate tissues. The truncated AR 
appears  to  have  three  to  five  times  more  potent 
transactivating activity than the full-length AR in re-
porter  assays.  In addition,  Lapouge  reported  that  a 
mutation of Q640X identified in the hinge region of 
AR in metastatic prostate cancer lesions may generate 
a short form AR protein lacking LBD. This ARQ640X 
mutant exhibits strong and ligand-independent tran-
scriptional  activity  [25].  In  2005,  Ahrens-Fath  and 
Haendler reported that a novel AR transcript variant, 
designated as AR transcript variant 2 (GI:58535454) 
(also referred as AR45) in GenBank, encodes a 45-kDa 
protein  which  is  composed  of  a  unique  seven  ami-
no-acid N-terminal sequence, DBD, H and LBD [26]. 
This transcript may likely be resulted from an alter-
native  transcript  start  site  of  the  AR  gene.  AR45  is 
highly expressed in heart, to a lesser extent, in a vari-
ety of tissues including skeletal muscle, uterus, pros-
tate, breast and lung. Overexpression of AR45 may 
either repress or stimulate AR transcriptional activity 
depending on cellular context.  
Cloning and identification of alternatively 
spliced AR variants 
 Since  2008,  we  and  others  have  cloned  and 
identified multiple alternatively spliced AR variants 
[11-15].  We  initiated  our  search  for  potential  AR 
splicing variants based on the observation that a panel 
of  AR  shRNAs  targeting  different  exons  displayed 
differential knock-down effects on the 110-kDa  and 
80-kDa AR proteins, suggesting that AR and its short 
form  variant(s)  were  derived  from  more  than  one 
transcript. We performed 3’-RACE, and cloned mul-
tiple alternatively spliced AR isoforms. These variants 
are generated from alternative splicing through vari-
ous  mechanisms,  including  exon  skipping,  cryptic 
splicing donor or acceptor usage, cryptic exon inclu-
sion, etc. Because the sequences of two AR transcript 
variants  (the  prototype  AR  and  AR45)  are  already 
present in GenBank at the time when we deposited 
our  clone  sequences,  the  newly  identified  splicing 
variants were designated as AR3 (GI:224181613), AR4 
(GI:224181615),  AR5  (GI:224181619),  AR6 
(GI:224181621),  and  etc  [12].  In  addition  to  the 
isoforms we reported, several other groups also re-
ported  a  variety  of  AR  splice  variants  identified  in 
their study. Dehm et al. reported two AR isoforms of 
AREx1/2/2b  and  AR1/2/3/2b  [11].  Hu  et  al.  described 
AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, and 
AR-V7  [13]. Sun  cloned ARv567es (GI:270358641)  in a 
castration-resistant  xenograft  [14].  Watson  reported 
AR-V8 and AR-V9 as well as two mouse Ar vairants 
mV-1 and mV-4 [15]. These AR isoforms retain NTD 
and DBD, but lack LBD. Based on currently available Int. J. Biol. Sci. 2011, 7 
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sequence data in GenBank, a schematic illustration of 
AR and its splice variants is summarized in Figure 1. 
Among the AR isoforms identified so far, AR3 (a.k.a. 
AR-V7 based on protein sequence homology) appears 
to  be  one  of  the  major  constitutively  active  AR 
isoforms  in  prostate  cancer  cell  lines  and  human 
prostate tissues [12, 13, 27]. Expression of AR3/AR-V7 
protein  in  various  human  prostate  cancer  cell  lines 
and  tissues  has  been  reported  in  two  independent 
studies  [12,  13].  Meanwhile,  existence  of  a  protein 
product  derived  from  other  AR  splice  variants  re-
mains to be validated. 
 
 
 
Figure 1. Schematic structure of human AR splice variants reported in GenBank. The hatched cassettes stand for the cryptic 
exons. Solid thick lines represent the transcribed exon sequences. U: unique N- or C-terminal sequence. 
 
Function of AR splice variants 
Given much less abundance of AR splice vari-
ants compared to the prototype AR, one of the key 
issues has been debated in the field ever since their 
discovery is whether these isoforms are of functional 
importance  or  they  are  just  by-products  of  splicing 
process of AR gene. Several lines of evidence support 
important  roles  of  these  variants  in  prostate  cancer 
biology. It has been shown that selective knock-down Int. J. Biol. Sci. 2011, 7 
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of AR3 expression (without altering the prototype AR 
protein level) in CWR-R1 and 22Rv1 cells significantly 
inhibit their growth under androgen-depleted condi-
tions [12]. The potential role of AR splice variants in 
driving  prostate  cancer  progression  is  further  sup-
ported  by  several  independent  clinical  correlation 
studies  [12,  13,  27].  The  high  expression  level  of 
AR3/AR-V7  can  predict  biochemical  recurrence  as 
well  as  cancer-specific  survival,  suggesting  that 
AR3/AR-V7 may have a strong potential to serve as a 
prognostic  marker  independent  of  AR.  These  data 
support the notion that AR3 may play a critical role in 
prostate cancer biology. 
In  terms  of  transcription  activity,  several  AR 
variants  have  been  shown  to  induce  lig-
and-independent activation of ARE-driven reporters 
in the absence of androgens. However, the functions 
of these AR isoforms should not be simplified as a 
mere substitution for the prototype AR as they may 
have  significant  distinct  functions.  We  and  others 
showed that AR3/AR-V7 and ARv567es isoforms have 
unique target gene sets distinct from those regulated 
by the prototype AR [12, 14]. A gene expression pro-
filing study revealed that AR3 shares some overlap-
ping target genes with AR despite its lack of the AF2 
domain (LBD) [12]. Therefore, AR3 may play a dis-
tinct  yet  essential  role  in  androgen-independent 
growth  through  regulating  a  unique  set  of  target 
genes including AKT1, which are not regulated by the 
prototype AR. These genes are involved in regulation 
of  diverse  biological  processes  including  signal 
transduction,  posttranslational  modifications,  tran-
scription,  chromatin  remodeling,  ion  transportation 
and  metabolism,  suggesting  that  AR3  may  play  a 
critical role in homeostasis maintenance of its target 
cells. It is also noteworthy that several genes prefer-
entially regulated by AR3, such as HOXB7, are known 
to  be  involved  in  inhibition  of  differentiation.  AR3 
may therefore play a role in inhibiting differentiation 
or  inducing  dedifferentiation  of  prostatic  epithelial 
cells during development of prostate cancer. In addi-
tion, another target gene differentially regulated by 
AR and AR3 is TAF9B, which encodes one of the small 
subunits of the general transcription complex TFIID 
and functions as a basal transcriptional co-activator in 
promoter  recognition  and  transcription  complex  as-
sembly. TAF9B appears to be positively regulated by 
AR3  while  negatively  regulated  by  AR  in  both 
CWR-R1  and 22Rv1  cells, suggesting it may play a 
role in differential transcription regulation mediated 
by AR3 and AR. Further experiments are needed to 
test whether TAF9B plays a role in determination of 
the promoter specificity associated with AR or AR3. It 
is very likely that AR and AR3 may function inde-
pendently, cooperatively or competitively depending 
upon the context of promoters and cell types.  
Despite  of structural similarity,  these AR  vari-
ants may exert their unique cellular functions, in a cell 
context dependent manner, due to their presence in 
different subcellular compartments. For example, in 
transiently transfected COS-1 or LNCaP cells, AR3 is 
primarily localized in the nucleus, suggesting a role in 
regulating  gene  transcription.  AR4  appears  to  be 
mainly  located  in  the  cytoplasm,  suggesting  that  a 
cytoplasmic function. Another AR splice variant AR8 
is associated with the plasma membrane (Yang and 
Qiu unpublished data). It is notable that subcellular 
localization of a given AR isoform could be dynamic 
and vary in different cell types. For instance, unlike in 
COS-1 and LNCaP cells, localization of AR3 in tran-
siently transfected DU145 cells is quite heterogeneous 
and diffused in cytoplasm in about 50% of cells (Fig-
ure 2).  
In benign prostate tissue, AR3 protein is mainly 
present in basal and stromal cells whereas barely de-
tectable  in  luminal  epithelial  cells  (Figure  3)  [12]. 
However,  an  increase  of  AR3  expression  is  readily 
detected in luminal cells in the adjacent PIN lesions 
and majority of malignant luminal cells, suggesting a 
potential role of AR3 in tumor initiation and devel-
opment. Although the expression level of AR3 protein 
is increased, AR3 is mainly found in the cytoplasm in 
most of hormone naïve tumors while nuclear-positive 
staining is detected in over 40% of hormone refractory 
tissues,  suggesting  that  AR3  nuclear  translocation 
may be correlated with androgen independence. It is 
possible  that  AR3  transcriptional  activity  is  tightly 
regulated by its subcellular localization like the pro-
totype AR. It is still unclear what are the mechanisms 
underlying regulation of AR3 nuclear translocation. 
The nuclear translocation signal of AR3 could be dif-
ferent from that of AR due to the lack of K630, K632 
and K632 residues essential for AR nuclear transloca-
tion  [28,  29].  The  16-a.a.  unique  sequence  at  the 
C-terminus could reconstitute a new nuclear translo-
cation signal for AR3 (Guo and Qiu unpublished da-
ta). We previously showed that Src kinase may regu-
late AR nuclear translocation independent of andro-
gens, possibly through phosphorylating Y534 in the 
NTD [30]. Most of Src-induced tyrosine phosphoryla-
tion  sites  are  clustered in  NTD  and also  present in 
AR3  and  Src  inhibitors  could  prevent  the  nuclear 
translocation of AR3 in CWR-R1 cells (Guo and Qiu 
unpublished data). Therefore, Src family kinases may 
be involved in regulating AR3 activity. 
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Figure 2. Subcellular localization of AR3/AR-V7. COS-1 and DU145 cells were transfected with an AR3 expressing plasmid. 
At 48h post-transfection, cells were stained with an anti-AR N-terminal antibody (green) and nuclei were visualized with 
DAPI (blue). In DU145 cells, both nuclear and cytoplasmic staining is observed. 
 
 
Figure 3. Immunohistochemistry analysis on human prostate tissue sections using the AR3 specific antibody (ref [12]). Left, 
in benign tissues, AR3 is primarily detected in stromal and basal compartments whereas virtually no expression in luminal 
epithelial cells. Center, in adjacent prostatic intraepithelial neoplasia (PIN), AR3 is detectable in luminal epithelial cells. Right, 
in hormone-resistant (HR) tumors, nuclear staining of AR3 is enhanced. 
 
It is still under debate whether AR is expressed 
in basal cells in prostate. Based on our immunohisto-
chemistry analysis using an AR N-terminus antibody, 
a weak positive staining is detectable in some basal 
cells.  Such  relatively  weaker  signal  could  easily  be 
neglected  when  compared  to  much  stronger  AR 
staining in luminal epithelial cells. The presence of AR 
transcript in purified basal cells is further confirmed 
by a recent study [31]. The expression of AR3 in basal 
cells is readily detectable due to the lack of AR3 ex-
pression in luminal epithelial cells in benign prostate 
gland. It should be noted that AR3 staining is quite 
heterogeneous in most of tumor samples we exam-
ined, suggesting that AR3 may only be required for a 
subpopulation  of  tumor  cells.  However,  we  cannot 
exclude  the  possibility  that  AR3-positive  cells  may 
influence  their  surrounding  cells  via  an  indirect 
manner,  such  as  releasing  autocrine/paracrine  fac-
tors.  
Although we are unable to detect direct interac-
tion between endogenous AR3 and AR, ARv567es has 
been  reported  to  associate  with  AR  under  overex-
pression  conditions  and  modulate  AR  transcription 
activity [14]. The existence of various AR isoforms and 
their potential functions in modulating AR transcrip-
tion  activity  may  explain  why  the  AR  replacement Int. J. Biol. Sci. 2011, 7 
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strategy described in our previous study could only 
partially rescue the AR activity [30]. The AR shRNA 
that  we  used  in  the  knockdown  experiments  could 
target not only the prototype full-length AR but also 
the other less abundant AR transcript variants, such 
as  AR2,  ARv567es  and  possibly  other  unidentified 
isoforms. It may require restoration of more than just 
the  full-length  AR  to  fully  rescue  the  complicated 
endogenous AR function, suggesting that optimal AR 
transcription activity may very likely dependent upon 
other splice variants in prostate cells. 
Several  independent  studies  showed  that  AR 
splice  variants,  AR3/AR-V7  and  AR4/AR-V1,  are 
upregulated  in  hormone  refractory  prostate  tumors 
compared with hormone naïve counterparts [12, 13, 
27]. Increase of the AR3/AR-V7 variant expression in 
prostate cancer cell lines in response to androgen ab-
lation is also demonstrated [15]. A recent report sug-
gest that increased expression of AR splice variants is 
associated with amplification of the AR locus in hu-
man prostate cancer cell line 22Rv1 and a subset of 
human prostate tumors [32]. It is noteworthy that, in 
22Rv1 cells, despite AR amplification, the level of AR 
protein is not increased accordingly while the trun-
cated AR splice variants appear to become dominant. 
AR amplification is reported in about 20% of hormone 
refractory prostate cancer, however, AR protein levels 
in  hormone-resistant  tumors  with  and  without  AR 
amplification are not significantly different [33]. This 
raises  the  possibility  that  “overproduction”  of  AR 
variants  resulted  from  AR  amplification  in  castra-
tion-resistant  tumors  actually  plays  a  rate-limiting 
and essential role in disease progression. The relative 
expression  level  of  AR  and  AR  isoforms  may  vary 
among different prostate cancer cell lines and tissues, 
possibly regulated by a variety of extracellular stimuli 
and environmental perturbation. The relative expres-
sion level of AR variants to AR is altered under dif-
ferent  culture  conditions,  such  as  cell  density.  This 
implies that intercellular communication via cell ad-
hesion  and/or  autocrine/paracrine  factors  may  in-
fluence the expression of AR isoforms. In addition, the 
expression  level  of  AR  splice  variants  may  also  be 
influenced by the level of AR protein under certain 
cell culture conditions. To selectively knockdown the 
prototype AR, we need to consider cell density as well 
as dose of shRNAs used for knockdown experiments. 
In our lenti-virus based shRNA knock-down experi-
ments, selective knock-down of AR by the AR shRNA 
targeting at Exon 6 could be achieved under appro-
priate experimental conditions [12, 30]. However, we 
do observe that if very high doses of AR shRNA are 
used and when cell density is low, the expression of 
AR3 may be altered (Guo and Qiu, unpublished data). 
The  change of  AR3  transcript  is  likely  caused  by a 
posttranscriptional  regulation  mediated  by  AR  pro-
tein as the level of AR pre-mRNA is not affected. An-
other  possible  explanation  could  be  that  there  are 
more than one AR3 transcripts with different 3’UTR 
could  be  present  in  these  cells.  Some  of  them  may 
contain  a  sequence  from  Exon  5-8  of  the  AR  gene. 
However, so far, we have not yet detected such kind 
of transcripts in CWR-R1 cells. In addition, we cannot 
exclude  the  possibility  that  during  the  lenti-virus 
based  knockdown  process  (routinely  requires  2-3 
days), some kind of secondary effects,  such as per-
turbation  of  certain  components  of  the  splice  ma-
chinery by viral infection, may indirectly alter AR3 
expression. Nevertheless, these observations strongly 
suggest a functional interaction between AR and AR 
splice variants. 
Taken together, these studies suggest that AR3 
may  have  a  distinct  biological  activity  despite  par-
tially overlapping with AR. AR3 may primarily play a 
role in the regulation of androgen-independent bio-
logical  processes  and  maintain  homeostasis  of  the 
prostate  gland  in  concert  with  AR.  Deregulation  of 
AR3 may play a role in the initiation, development 
and progression of prostate cancer.  
Perspectives 
Multiple  AR  transcript  variants  have  been 
cloned and identified so far. Given that the AR gene is 
composed of at least eight exons and large introns, it 
is  likely  that  increasing  numbers  of  the  AR  splice 
variants will be identified in future cloning and se-
quencing effort. Development of sensitive and reliable 
isoform-specific  antibodies  for  clinical  applications 
could be quite challenging despite of some promising 
correlation data derived from a small cohort study. 
Specific  detection  of  each  of  these  variants  by 
PCR-based methods in clinical samples may require 
more careful design of the amplification primers as 
every single exon in the AR gene could be a subject of 
exon skipping during splicing process. The ideal PCR 
primers should allow the amplified fragment cover all 
coding  exons  present  in  each  variant  to  assure  a 
faithful representation of the corresponding AR iso-
form. Failure to do so may generate misleading data. 
Designing the variant specific primer recognizing the 
unique  exon-exon  junction  would  also  help  to  dis-
criminate  other  similar  transcripts  generated  from 
usage of cryptic splicing donor/acceptor which may 
often cause frame shift in the coding region. The ex-
pression pattern of AR splice variants could be very 
dynamic in response to various intracellular and ex-
tracellular  cues.  The  dynamic  repertoire  of  AR  and 
AR variants may provide a sophistic regulatory sys-Int. J. Biol. Sci. 2011, 7 
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tem  to  orchestrate  cellular  responses  to  androgens 
and other extracellular stimuli. The future challenge 
would  be  how  to  individually  characterize  each  of 
these AR variants if their expression level is extremely 
low compared to the prototype AR or their expression 
may be restricted to certain cell type or stage. Given 
the relatively low expression of these splice variants, 
it is important to demonstrate how they exert their 
unique  functions  independently,  cooperatively  or 
competitively with AR. Due to the nature of hetero-
geneity  in  prostate  cancer,  study  on  the  potential 
functional interaction as well as independence of AR 
and AR variants in various prostate cancer cell lines 
and xenograft models would provide comprehensive 
understanding  of  the  role  of  AR  variants.  Some  of 
these variants may serve as a rate-limiting factor in 
certain cellular process or highly expressed in certain 
subtype of cells (such as stem/progenitor and neu-
roendocrine-like  cells)  despite  apparent  low  abun-
dance  in  a  pool  of  mixed  cell  population.  Further-
more,  identification  of  what  splicing  factors  are  in-
volved in exon selection in the context of the AR gene 
could potentially uncover new drug targets as dereg-
ulation of splicing of a group of genes are associated 
with prostate cancer progression. Further investiga-
tion  on  the  mechanisms  by  which  AR  variants  are 
regulated will allow us to better understand the com-
plicated  role  of  AR  in  prostate  cancer  biology  and 
develop  new  biomarkers  and  more  effective  thera-
peutics to fight prostate cancer.  
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